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A B S T R A C T
Although there have been reports of promising results regarding the transplantation of mesenchymal stem cells
(MSCs) for neurodegenerative diseases through the use of neuronal differentiation or control of the micro-
environment, traditional surgical transplantation methods like parenchymal or intravenous injection have
limitations such as secondary injuries in the brain, infection, and low survival rate of stem cells in the target site.
Focused ultrasound (FUS) treatment is an emerging modality for the treatment of brain diseases, including
neurodegenerative disorders. The various biological effects of FUS treatment have been investigated; therefore,
the goal is now to improve the delivery efficiency and function of MSCs by capitalizing on the advantages of FUS.
In this study, we demonstrated that FUS increases MSC transplantation into brain tissue by >2-fold, and that this
finding might be related to the activation of intercellular adhesion molecule-1 in endothelial and subendothelial
cells and vascular adhesion molecule-1 in endothelial cells.
KEY resources table
Reagent or resource Source Identifier
Antibodies
Mouse monoclonal anti-ICAM-1 Santa cruz biotechnology sc-8439
Mouse monoclonal anti-VCAM-1 Santa cruz biotechnology sc-13,160
Rabbit monoclonal anti-Iba1 Wako chemicals 019–19,741
Rabbit polyclonal anti-GFAP Abcam ab116010
Mouse monoclonal anti-Rat
RECA-1
Bio-rad MCA970R
Experimental Models: Cell Lines
Bone marrow-derived mesench-
ymal stem cells
Stem Cell Res Ther. 2015 Sep
15;6:174.
N/A
Other
Definity Lantheus Medical Imaging N/A
1. Introduction
Diseases of the central nervous system (CNS), such as Alzheimer's
disease (AD) and Parkinson's disease (PD), usually result in degenera-
tion and irreversible damage to the structures and functions of the
brain, which is often accompanied by serious cognitive or physical
impairments. Many types of novel therapeutic modalities, including
targeted medicine (Danon et al., 2019), deep brain stimulation
(Lozano et al., 2019), radiosurgery (Jang et al., 2015), and stem cell
treatment (McLauchlan and Robertson, 2018), have been evaluated for
the treatment of patients with CNS diseases (Chang and Chang, 2017);
however, there remains no consensus regarding the choice of effective
therapy for neurodegenerative diseases.
Stem cell therapy represents a promising treatment modality for
CNS diseases, with positive outcomes and the feasibility of the tech-
nique being confirmed in recent years (Kamelska-Sadowska et al.,
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2019). Early in their development, stem cell applications focused on the
replacement of damaged neural structures with neural stem cells
(NSCs). One of the goals of NSC therapy is the replacement of dopa-
minergic neurons in PD, which is characterized by progressive degen-
eration of dopaminergic neurons in substantia nigra compacta, and
many preclinical and clinical trials have been conducted for this pur-
pose (Trounson et al., 2011). Previous studies reported that human
NSCs (hNSCs) completely restored and ameliorated the functional de-
fects in 6-hydroxydopamine-induced Parkinsonian mice (Zuo et al.,
2017), and that autologous NSCs induced motor recovery and increased
dopamine uptake in the transplanted putamen of a patient
(Lévesque et al., 2009).
Although these results show acceptable outcomes, a few concerns
have also been raised, such as the reduced efficacy over long-term use,
surgical risks during transplantation, and the cost of treatment
(de Munter et al., 2014). Moreover, the application of NSC therapy to
treat CNS diseases has other limitations. Because transplanted NSCs
rarely make connections with existing neurons, results show poor
functional improvement, even after NSC treatment (Abeysinghe et al.,
2016). In addition, following the intravenous injection of NSC, a
number of NSCs cannot pass through the lungs, resulting in only a small
number of NSCs reaching their target area in the brain (Fischer et al.,
2009).
Mesenchymal stem cells (MSCs) have emerged as a possible candi-
date for stem cell therapy for CNS diseases (Azari et al., 2010). MSCs
exhibit various types of biological effects, including neuroprotective
and immunomodulatory effects (Cabanes et al., 2007). Because most
neurodegenerative disorders are accompanied by immune dysfunction,
MSCs are proposed as a potential candidate for the treatment of neu-
rodegenerative disorders (Abeysinghe et al., 2016). Previous studies
reported that MSCs reduced amyloid-β plaques in an AD mouse model
by secreting soluble intracellular adhesion molecule-1 (ICAM-1)
(Kim et al., 2011) and increased neurogenesis in the subventricular
zone and differentiation of neural precursor cells into dopaminergic
neurons in the substantia nigra in a PD model (H.J. Park et al., 2012).
Additionally, clinical trials support the therapeutic efficacy of MSCs in
PD, stroke, and multiple system atrophy (Buckner, 2010; Honmou et al.,
2011; Venkataramana et al., 2010). However, the application of MSCs
also has limitations, especially regarding transplantation modalities
related to poor efficacy of delivery and survival rates.
Recently, a new treatment for CNS diseases by using focused ul-
trasound (FUS) was developed. High-intensity FUS allows thermal ab-
lation of the target area into which the FUS energy is concentrated.
However, low-intensity FUS has multiple biological effects, including
blood-brain barrier (BBB) modulation, neuromodulation, immune
modulation, and changes to the cerebral microenvironment (Chang and
Chang, 2017; Curley et al., 2017; Kubanek, 2018; Shin et al., 2018).
Although a study suggested enhancing FUS-mediated trans-endothelial
migration of NSCs by using microbubbles (MBs) (Burgess et al., 2011),
the impact of the BBB during cell migration remains unknown, and the
effects of applying FUS with stem cells have only been explored at an
early experimental stage.
Therefore, this study aimed to determine whether non-invasive FUS
can facilitate the migration of MSCs to a target area in the brain and
investigated the in vivo effects of adhesion-molecule alterations in-
duced by low-intensity FUS in a rat model.
2. Materials and methods
2.1. Bone marrow-derived (BM)-MSC preparation
MSCs were purified, as previously described (Song et al., 2015).
Briefly, BM-MSCs were harvested from normal rat bone marrow and
maintained at 37 °C and 5% CO2. The culture medium used was Dul-
becco's modified Eagle medium (DMEM)-low glucose supplemented
with 10% fetal bovine serum(FBS)(Invitrogen, Carlsbad, CA, USA),
100 U/mL penicillin (Invitrogen), and 100 µg/mL streptomycin (In-
vitrogen). The medium was replaced every 2 or 3 days, and we used
BM-MSCs at the 5th passage. Cells at this passage were prestained using
the PKH26 red fluorescent cell linker kit (Sigma-Aldrich, St. Louis, MO,
USA) to identify PKH26 bound to the cell membrane.
2.2. Animals and MSC transplantation with FUS
All animal experiments were performed in accordance with the
Guide for the Care and Use of Laboratory Animals of the National
Institutes of Health and were approved by the Institutional Animal Care
and Use Committee of Yonsei University, Korea (IACUC number:
2018–0167). Rats were housed in groups of three per cage in a tem-
perature/humidity-controlled room with a 12-/12-h light/dark cycle
and with access to food and water ad libitum. Every effort was made to
minimize the number of rats used and overall animal suffering.
Thirty-three male Sprague–Dawley rats (200–220 g) were randomly
assigned to one of five experimental groups before sonication. Rats in
the normal group (n= 5) did not undergo any surgical procedures, and
those in the IV group (n = 7) underwent stem cell transplantation via
the tail vein without any surgical procedures. All sonication groups
(n = 21) were bilaterally sonicated with low-intensity FUS energy in
the lateral hippocampal area, with seven rats also receiving tail-vein
injection of BM-MSCs after 3 h. Rats in the FUS only group (n = 9)
underwent sonication only, and these rats were sacrificed 3 h after
sonication in order to confirm the expression of adhesion molecules.
The remaining rats (n = 5) were injected with Evans blue via the tail
vein 3 h after sonication to confirm BBB permeability at the time when
MSCs were infused.
Animals were deeply anesthetized with a mixture of ketamine
(75 mg/kg), acepromazine (0.75 mg/kg), and xylazine (4 mg/kg) and
secured in a stereotaxic frame. An FUS beam was targeted to the bi-
lateral hippocampal region (AP −3.5; ML ±2) using a 3D positioning
system. Definity (mean diameter range: 1.1–3.3 µm; Lantheus Medical
Imaging, North Billerica, MA, USA) MBs were diluted in saline and
injected intravenously into the tail vein 10 s prior to ultrasound soni-
cation. Evans blue (2%, 100 mg/kg) was injected intravenously at 3 h
post-sonication in the selected rats (n = 5), which were sacrificed
30 min later to examine BBB permeability.
Three hours after sonication, seven rats in the FUS+Cell group re-
ceived 200 µL of BM-MSCs (3 × 106 cells/200 μL) via tail-vein injec-
tion. Another seven rats in the IV group received 200 µL of BM-MSCs
(3 × 106 cells/200 μL) via tail-vein injection only. All rats were im-
munosuppressed with cyclosporine (12.5 mg/kg via daily in-
traperitoneal injection) starting the day before transplantation and
continuing up to the day they were sacrificed. These 14 rats were sa-
crificed at 24 h after stem cell transplantation.
2.3. FUS preparation and sonication parameters
FUS setup and sonication parameters were determined based on a
previous study (Shin et al., 2018). A single-element spherically focused
transducer (center frequency: 515 KHz; third harmonic: 1.6 MHz; focal
depth: 51.7 mm; and radius of curvature: 63.2 mm; H-107MR; Sonic
Concept Inc., Bothell, WA, USA) was driven by a waveform generator
(33220A: Agilent Technologies, Palo Alto, CA, USA) and radio-fre-
quency power amplifier (240 L; ENI Inc., Rochester, NY, USA). The
transducer electrical impedance was matched to the output impedance
of the amplifier (50 ΩS with an external matching network (Sonic
Concept Inc.). A cone filled with distilled and degassed water was
mounted onto the transducer assembly, and a needle-type hydrophone
(HNA-0400; Onda, Sunnyvale, CA, USA) was used for transducer cali-
bration to measure the acoustic beam profile in the tank filled with
degassed water. The sonication parameters involved a 10-ms burst
duration at a 1-Hz pulse-repetition frequency for a total duration of
300 s to generate average peak-negative pressures of 0.25 MPa
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2.4. Histopathologic analysis
All animals were anesthetized and perfused with normal saline and
cold 4% paraformaldehyde. The brains were stored in 4% paraf-
ormaldehyde (Duksan, Seoul, South Korea) for 3 days at 4 °C and
transferred to 30% sucrose (Duksan) for 3 days. The brains were then
cut into 30-μm coronal sections using a freezing microtome (Leica
Biosystems, Wetzlar, Germany) and stored in cryoprotectant solution
consisting of 0.1 M phosphate buffer (pH 7.2), 30% sucrose, 1% poly-
vinylpyrrolidone (Sigma-Aldrich), and 30% ethylene glycol (Thermo
Fisher Scientific, Rockford, IL, USA) at −20 °C. Fluorescence im-
munohistochemistry was performed to detect ICAM-1, vascular cell-
adhesion molecule (VCAM-1), glial cells, and endothelial cells. Sections
were blocked with 5% normal goat serum (Vector Labs, Burlingame,
CA, USA) and incubated with primary antibodies at the following di-
lutions: ICAM-1 (sc-8439; Alexa Fluor 488; 1:100; Santa Cruz
Biotechnology, Dallas, TX, USA), VCAM-1 (sc-13,160; Alexa Fluor 647;
1:100; Santa Cruz Biotechnology), microglia (Iba1; 019–19,747; 1:300;
Wako Chemicals, Richmond, VA, USA), astrocytes (glial fibrillary acidic
protein; ab116010; 1:300; Abcam, Cambridge, UK), and endothelial
cells (RECA-1; MCA970R; 1:300; Serotec, Oxford, UK). After the pri-
mary immunoreaction, sections were incubated with secondary anti-
bodies conjugated with Alexa Fluor 647 (AF647; A20991; 1:300;
Thermo Fisher Scientific) or Alexa Fluor 488 (AF488; A11001; 1:300;
Thermo Fisher Scientific). The staining intensity of the sections was
visualized with an LSM 700 confocal microscope (Carl Zeiss, Jena,
Germany).
Hematoxylin (Vector Labs) & eosin (Sigma-Aldrich) (H&E) staining
was performed to examine brain-tissue damage and red blood-cell ex-
travasation. Brains were processed for paraffin-wax embedding and cut
into 4-µm sections, which were stained with H&E.
The BBB opening was confirmed by histological assessment of the
gross tissue sections and the presence of Evans blue extravasation in the
FUS-sonicated region of the brain.
2.5. Statistical analysis
All data are expressed as the mean ± standard error of the mean
(SEM). Because counting data were not normally distributed
(D'Agostino and Pearson omnibus normality test: the N was too small),
nonparametric analysis was performed using the two-tailed non-para-
metric Mann–Whitney test. SPSS (v.22.0; IBM Corp. Armonk, NY, USA)
was used for statistical analysis, and a p < 0.05 was considered sta-
tistically significant.
2.6. Key resource table
Other details for reagents and chemicals used in this study are de-
tailed in the key resource table.
3. Results
3.1. Effects of FUS on enhancing MSC trans-endothelial migration
To analyze the effects of FUS on trans-endothelial MSC migration,
we compared five rats not receiving FUS (control) with seven rats re-
ceiving FUS after injection of PKH26-prestained MSCs (FUS group) via
the tail vein. The whole hippocampal region, which was the FUS-target
area, was transected from the anterior end to the posterior end with a
30-μm width in both groups, and PKH26-positive cells in each coronal
section were counted and summed for comparison. The mean number
of PHK26-positive cells in the hippocampal region in the control group
was 739.6 ± 104.0, whereas that in the FUS group was 1700.7 ± 111.8
(p = 0.02), indicating that FUS significantly increased the yield of
trans-endothelial migrated MSCs (Fig. 1).
3.2. Effect of FUS on ICAM-1 and VCAM-1 expression
Five rats without any intervention (control) and nine rats receiving
FUS sonication in the hippocampal region (FUS group) were used to
analyze the effect of FUS on ICAM-1 and VCAM-1 expression. The same
three slices of the hippocampal region in both groups were selected for
immunohistochemistry, and cells reactive to antibodies for ICAM-1 and
VCAM-1 were counted for comparison. The mean number of ICAM-1-
positive cells in the control group was significantly lower than that in
the FUS group (167.5 ± 30.7 vs. 356.9 ± 57.6, respectively;
p= 0.003). Similarly, the mean number of VCAM-1-positive cells in the
control group was significantly lower than that in the FUS group
(199.9 ± 27.0 vs. 335.0 ± 44.7, respectively; p = 0.003) (Fig. 2).
Analyses of ICAM-1 and VCAM-1 co-localization with other cells,
such as glial cells and microglia, were performed in the dentate gyrus,
hilus of hippocampus, cornu ammonis (CA)1, and CA3. The results
showed that ICAM-1 was expressed in both glial cells and microglia,
whereas VCAM-1 expression was mainly observed in endothelial cells
across all hippocampal structures (Fig. 3).
3.3. Microglial activities after FUS
Microglia are a type of glial cell located throughout the CNS, ac-
counting for 10–15% of all cells found within the brain (Xavier et al.,
2014). As resident macrophages, they act as the first and main form of
active immune defense in the CNS (Filiano et al., 2015). Because mi-
croglia are mainly associated with the immune response, we de-
termined whether there were changes in microglia after FUS. As shown
in Fig. 4, microglial activities were markedly increased after FUS.
Evaluation of damage to the brain region by H&E staining revealed no
visible structural injuries or extravasated red blood cells in sonicated
brain regions (Fig. 5), indicating that FUS induced an inflammatory
reaction without structural damage.
3.4. Evans blue extravasation at the time when MSC was infused
To confirm BBB permeability when MSC was injected, we examined
five rats injected with Evans blue 3 h after FUS sonication. Leakage of
Evans blue was visualized in the sonicated hippocampal region. To
show the dye leakage obviously, Evans blue fluorescence (excitation at
620 nm, emission at 680 nm) was detected in cryostat sections of brain
tissue using LSM 700 confocal microscopic imaging.
4. Discussion
In this study, we focused on the biological effect of FUS in regard to
stem cell homing and determined whether FUS sonication at a specific
area of the brain could non-invasively increase the efficacy of stem cell
transplantation. In the FUS-treated group, we observed a >2-fold in-
crease in MSC migration relative to that observed in the untreated
group and verified the upregulated expression of cell-adhesion mole-
cules (CAMs) ICAM-1 and VCAM-1 in the FUS treated group.
Interestingly, both ICAM-1 and VCAM-1 were expressed in endothelial
cells, whereas only ICAM-1 was expressed in subendothelial cells, such
as astrocytes and microglia, even without structural injury and he-
morrhage. A previous study reported that the activation of CAMs is
related to stimulation by various cytokines, and that stem cells migrate
to the activated site (Nitzsche et al., 2017). Therefore, our results
suggest that increased FUS-induced expression of ICAM-1 and VCAM-1
could be associated with the targeted homing of MSCs, although further
studies are required to confirm this finding.
4.1. Non-invasive and targeted MSC transplantation into the brain using
FUS
Many clinical trials focused on the treatment of CNS diseases using
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stem cells have been conducted; however, few have reported successful
outcomes, despite preclinical studies for each disease model showing
excellent therapeutic effects. These unfavorable results could be asso-
ciated with various factors, including the number of transplanted stem
cells, biological properties of each stem cell, and route of transplanta-
tion. Given that the number of stem cells in the target area is a critical
factor for successful treatment, invasive surgical methods, including
direct transplantation and transplantation using a catheter and re-
servoir implantation, have been used (Baek et al., 2012; Park et al.,
2018). However, because these modalities require direct injection or
implantation into the brain parenchyma, surgical complications may
occur.
Other strategies to improve MSC homing include modulation of
stem cells to exhibit reactivity to migratory stimuli and alteration of
target sites to attract stem cells (Naderi-Meshkin et al., 2015). These
strategies include treatment of MSCs with chemical compounds
(Tsai et al., 2011), preconditioning with hypoxia (Liu et al., 2012),
genetic modifications (Bobis-Wozowicz et al., 2011), and coating with
antibodies (Gundlach et al., 2011). Additionally, target-site modulation
to attract MSCs involves direct injection of chemokines (Segers et al.,
2007) and direct transfection of target tissue with chemokine-encoding
genes (Penn et al., 2013). However, these methods have limitations.
Treatment with various factors or genetic alteration of MSCs can cause
unwanted side effects, including degradation of MSC function and an-
gioma formation (Phillips and Tang, 2008; Udalamaththa et al., 2016),
and modulation of the target site through direct application into the
tissue is still invasive.
Apart from the previously mentioned somewhat invasive and in-
efficient methods, magnetic guidance (Yun et al., 2018) and radio-
therapy (Mouiseddine et al., 2007), are two relatively non-invasive
methods that have been developed. However, these methods also have
limitations in terms of targeted delivery, as magnetic guidance cannot
reach deep areas of the brain, and radiotherapy can cause unnecessary
tissue injuries. Additionally, when applying stem cell therapies to the
brain, the BBB can hamper the entry of stem cells into the CNS
(de Munter et al., 2014). Several studies have utilized FUS as a means to
overcome these limitations.
Previous studies evaluated the effect of FUS on stem cell application
in various organs. Ghanem et al. applied FUS to a rat model of acute
myocardial infarction to promote stem cell grafting in a “proof of
Fig. 1. Comparison of transplantation yield between the control and FUS groups. Immunohistochemistry results of PKH26-positive cells in the hippocampal region
(A) and statistical analysis of the difference between groups (B) 'Cell only’ indicates the control group, and “Cell+FUS” indicates the group receiving cell trans-
plantation with FUS. Data are expressed as the mean ± SEM.
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concept” study involving intravenous transplantation of MSCs, resulting
in cell numbers in the myocardium ~50% to 60% higher in the FUS
group than in the untreated group (Ghanem et al., 2009). Furthermore,
they found that the activities of cytokines, such as interleukin (IL)−1β,
tumor necrosis factor (TNF)-α, and matrix metalloproteinase, increased
in the FUS-treated group, and this effect was possibly related to the
increased trans-endothelial migration of MSCs. Another study reported
the use of FUS without MBs for targeted homing of stem cells
(Burks et al., 2013), where intravenous injection of MSCs and en-
dothelial precursor cells along with FUS treatment was applied to
skeletal muscle. The results indicated achievement of maximal stem cell
delivery when FUS was performed before cell infusion, and this was
possibly due to the increased activities of chemo-attractants. Interest-
ingly, they observed increased stem cell homing when FUS treatment
and cell infusion were repeated daily, which indicated that the number
of targeted cells can be modulated and substantially increased over
short periods of time, regardless of the type of stem cell.
Recently, simultaneous application of FUS treatment with MB and
stem cell transplantation into the brain was investigated (Burgess et al.,
2011). The histological and immunohistochemical results obtained
after FUS treatment of the brain prior to NSC transplantation indicated
the presence of living NSCs in the targeted area of the brain. Limited
tissue damage was confirmed by H&E staining that showed red blood
cell extravasation. Although the vascular microstructure in the brain
differs from that in other organs due to the unique microstructure of the
BBB, it demonstrated the efficacy of FUS-mediated inducement of stem
cell homing in the brain.
In the present study, we determined whether FUS treatment with
MB could enhance MSC homing to the target area without causing
structural brain injury such as red blood cell extravasation. FUS treat-
ment was targeted to the hippocampus region, because the hippo-
campus is a potential target for cognitive-related disorders, which re-
presents one of the major indications of MSC treatment (Cho et al.,
2018). We used BM-MSCs without any pretreatment, such as hypoxic
preconditioning or treatment with chemical compounds and in the
absence of any factor that could possibly artificially modulate the mi-
croenvironment of the target site. Burgess et al. delivered NSC to a rat
brain using FUS with MB in acutely, resulting in NSC migration to the
parenchyma (Burgess et al., 2011). In the present study, we applied
MSCs to a rat brain using FUS with MB 3 h after sonication. Counting of
MSCs in the whole hippocampus in both groups showed a >2-fold
higher average number of MSCs in the hippocampus in the FUS-treated
group than in the untreated group (Fig. 1; p = 0.002). This result
suggests the possibility that the application of ultrasound can efficiently
transfer other stem cells through the BBB to the brain parenchyma.
Alkins et al. evaluated whether FUS treatment could increase immune-
cell migration into the targeted area of the brain, revealing that FUS
treatment enhanced immune-cell migration by ~2-fold relative to that
in the control group (Alkins et al., 2013). This result was comparable to
the transplantation yield of MSCs with FUS-treatment in the present
study and suggests that, similar to the immune-cell response to FUS
treatment, FUS treatment can enhance trans-endothelial migration of
MSCs into brain tissue.
Our findings address the limitations of invasiveness and low-de-
livery efficiency of transplantation methods and demonstrated a
method for enhancing MSC homing noninvasively with higher efficacy
to desired brain regions.
4.2. Role of CAMs and microglia activation in FUS-mediated targeted MSC
transplantation into the brain
Stem cells exhibit a homing response to injured tissues mediated by
the increased expression of chemokine receptors or enhanced secretion
of chemokines by the injured tissue (Karp and Leng Teo, 2009). FUS can
not only selectively focus activity to specific areas of the tissue but can
also target deep structures using magnetic resonance image technology
without affecting other tissues. At the target region, the mechanical
pressure applied by sound waves induces various biological effects.
Previous studies demonstrated that FUS sonication with MBs to the
brain can cause a sterile inflammatory response by upregulating a
variety of inflammatory and trophic factors (Kovacs et al., 2017)
(McMahon and Hynynen, 2017); however, MSC homing to the brain
has not yet been assessed using this method. IL-1β or TNF-α are po-
tentially related to the chemotactic migration of MSCs toward the en-
dothelium and across matrix barriers according to a myocardial in-
farction model (Ghanem et al., 2009; Segers et al., 2006). However,
aside from the trans-endothelial migration induced by chemotactic
agents, the tight attachment of MSCs to the endothelium under high-
Fig. 2. Immunohistochemical analysis of ICAM-1 and VCAM-1. Expression of
both ICAM-1 and VCAM-1 was higher in FUS-treated rats (B) than in untreated
rats (A) Comparison of ICAM-1(C) and VCAM-1(D) between the control and
FUS groups. Data are expressed as the mean ± SEM.
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flow conditions is also critical for targeted MSC transplantation. Here,
we determined whether the expression of CAMs was enhanced fol-
lowing FUS treatment. The endothelium of the target tissue can possess
a molecular signature that helps determine the specificity of the local
immune response through binding to homing receptors, such as VCAM-
1 and ICAM-1, when MSCs are delivered systemically
(Dominguez et al., 2015). Moreover, coating MSCs with antibodies to
ICAM-1 can promote MSC attachment to endothelial cells in vitro under
high-flow conditions (Ko et al., 2009). Therefore, we confirmed the
ICAM-1 and VCAM-1 levels, finding marked FUS-induced increases in
ICAM-1 expression in endothelial cells (Figs. 2 and 3), which possibly
indicates a mechanism of targeted MSC transplantation, where FUS
induces MSC binding to endothelial cells in the target area. Interest-
ingly, ICAM-1 expression in subendothelial cells, such as astrocytes,
also increased (Fig. 2 and 3). ICAM-1 in subendothelial cells plays a role
in transporting drugs across the BBB (Hsu et al., 2014); therefore, this
result suggested that increased ICAM-1 levels in subendothelial cells
also affect targeted MSC transplantation. Additional studies, however,
are needed to clarify this conclusion.
Regarding why ICAM-1 was activated by FUS, various cytokine
stimulations are related to ICAM-1 activation, and disease-like condi-
tions can result in ICAM-1 overexpression (Hsu et al., 2014). In the
present study, microglia were activated by FUS, even in the absence of
structural injury (Fig. 4), indicating that FUS induced disease-like
conditions without structural damage. Moreover, this might be a reason
for ICAM-1 overexpression and enhanced MSC trans-endothelial mi-
gration.
Additionally, VCAM-1 expression in endothelial cells was elevated
by FUS treatment (Figs. 2 and 3). VCAM-1 can enhance stem cell
homing because of its propensity to make vessels resistant to detach-
ment (Chigaev and Sklar, 2012). A previous study of the systemic de-
livery of MSCs in mice with inflammatory bowel disease (IBD) showed
that coating MSCs with antibodies against VCAM-1 increased their ef-
ficacy to improve IBD (Ko et al., 2010). The increased expression of
ICAM-1 and VCAM-1 induced by FUS might be related to the targeted
homing of MSCs, although further studies are required to confirm this.
4.3. Safety issues associated with using FUS for MSC delivery
There are several possible issues associated with using FUS treat-
ment for MSC transplantation. First, the safety of the FUS treatment
should be guaranteed before being applied in humans. In this study, we
selected the sonication parameters using MBs based on the results from
a previous experiment by our group, and we verified the absence of
FUS-induced injury with microscopic examination (Fig. 5). ICAM-1 and
VCAM-1 are related to the inflammatory response (Hua, 2013;
Fig. 3. CAM co-localization. Co-localization of ICAM-1-positive cells and astrocytes (A), endothelial cells (B), microglia (C) and VCAM-1 cells and endothelial cells
(D). Scale bar, 200 μm.
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Muro and Muzykantov, 2005), and a previous study reported a ten-
dency for MSCs to migrate to injured/inflammatory sites (Marquez-
Curtis and Janowska-Wieczorek, 2013). In the present study, we
showed elevations in ICAM-1 and VCAM-1 levels in FUS-sonicated re-
gions, implying that the inflammatory reaction is induced by FUS in the
targeted brain area. Additionally, Fig. 1 shows the quantitative results
indicating increased migration of stem cells to the target site. Therefore,
our results represent indirect evidence confirming the enhanced mi-
gration of stem cells to targeted regions induced by FUS using MBs.
Although there was no extravasation of red blood cells in our acute
model, it is necessary to observe long-term inflammatory responses,
because repeated inflammation can cause structural changes in tissues
(Downs et al., 2015).
Another issue involves the duration of BBB related to stem cell
homing. Burgess et al. confirmed that NSCs cross the BBB to enter the
brain parenchyma during FUS sonication (Burgess et al., 2011). Pre-
vious studies reported that the FUS-induced BBB opening persists for
extended periods of time (1–10 h) (Hynynen et al., 2005; Wang et al.,
2009). We experimentally confirmed through Evans blue leakage that
the BBB opening was maintained 3 h after FUS sonication (Fig. 6). Our
data also demonstrated enhancement in the homing of BM-MSCs to the
targeted brain region (Fig. 1). We chose an MSC-infusion time based on
studies describing MSC transplantation into various tissues 3 h after
FUS treatment (Burks et al., 2013; Tebebi et al., 2015).
In contrast to previously published data (Burgess et al., 2011), our
study parameters using the MBs did not appear to cause red blood cell
extravasation (Fig. 5). Therefore, we suggest that FUS successfully
promoted MSC delivery without tissue damage. However, as un-
controlled MB cavitation can damage sonicated tissue (Fan et al., 2012),
the use of acoustic feedback control (e.g., passive cavitation detection)
needs to be evaluated in future studies (Hua, 2013; Wu et al., 2014).
Additional studies with FUS treatment alone, without MBs, are neces-
sary to avoid the uncontrolled effects of cavitation.
5. Conclusions
FUS treatment is an emerging modality for the treatment of brain
diseases, including neurodegenerative disorders. The various biological
effects of FUS treatment have been investigated, and here, we de-
termined whether FUS treatment could increase the efficacy of stem cell
homing. Our results demonstrated that FUS increased MSC transplan-
tation into brain tissue by >2-fold and this effect was possibly related
to the activation of ICAM-1 in endothelial and subendothelial cells and
VCAM-1 in endothelial cells. The long-term safety of FUS treatment and
the combined effects of FUS treatment with other strategies for en-
hancing MSC homing require additional investigations.
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